



Financial Statements
for the 1st quarter of fiscal year ending March 31, 2019
(From Apr. 1, 2018 to Jun. 30, 2018)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

August 8, 2018

Highlights in Business Results



(unit: JPY million)

	Apr. - Jun. 2017 Results	Apr. - Jun. 2018 Results	Diff.	Year-over-Year
Net sales	13,240	13,936	695	5.3%
Operating profit	46	28	(17)	(38.6%)
Ordinary profit	148	80	(67)	(45.7%)
Profit attributable to owners of parent	238	22	(215)	(90.4%)
Basic earnings per share※	JPY 9.77	JPY 0.94	---	---

Exchange Rate (average during period)	US Dollar	111.09	109.07
	Euro	121.08	133.22
	(unit: JPY) Singapore Dollar	79.79	81.79

Increased in sales, but decreased in profit for the 1st Quarter of FYE Mar. 2019

Sales	Japan	-Increased sales of New Hemodialysis Machine "GC-X01" -Increased sales of Dysphagia related products	Overseas	-Decreased sales of Blood Bags and AV Fistula Needles
	Profit	-The influence of increased sales was offset by the increase in labor cost and R&D cost, resulting in operating profit -The addition of share of profit of entities accounted for using equity method was offset by the foreign exchange losses, resulting in ordinary profit -A change in decreased income taxes - deferred resulted in Profit attributable to owners of parent		


※We have conducted a share consolidation of common stock of JMS Co., Ltd. pursuant to which two (2) shares were consolidated into one (1) share effective as of October 1, 2017. Accordingly, the "Basic earnings per share" has been calculated assuming that such share consolidation has been conducted at the beginning of the previous fiscal year.

Summary by segment (geographical area)



(unit: JPY million)

Japan




[Sales]

Increased sales of New Hemodialysis Machine "GC-X01" raised net sales.

[Ordinary Income]

Despite the influence of sales increase, the increase in R&D cost by clinical trial costs for new product resulted in profit.

Singapore *



[Sales]


Increased sales of Safety Scalp Vein Needles for North America market raised net sales.

[Ordinary Income]

The influence of increased labor cost resulted in profit.

*This segment includes Indonesia local subsidiary.

China



[Sales]

Decreased sales of Infusion Sets for Japan market by production transfer to Philippines reduced net sales.


[Ordinary Income]

The influence of decreased sales and the increase of foreign exchange losses resulted in loss.

Summary by segment (geographical area)

(unit: JPY million)

Philippines




[Sales]

Increased sales of Infusion Sets for Japan market raised net sales.

[Ordinary Income]

The influence of increased sales reduced loss.

Others*



*This segment includes business activity of domestic subsidiaries, Germany, United States and South Korea.

~Product introduction~




Hemodialysis Machines


Hemodialysis machine is a device for pulling blood from a patient into an extracorporeal circuit. The blood is purified by a dialyzer and returned to the patient by the hemodialysis machine.

Sales by Business Segment


Apr. – Jun. 2017
 Apr. – Jun. 2018
 (unit: JPY million)



Sales increase or decrease (Customer's Location)




(unit: JPY million)



Selling, General and Admin. Expenses



(unit: JPY million)




(unit: JPY million)

	Apr. - Mar. 2017	Apr. - Mar. 2018	Diff.	Year-over-Year
Labor Cost	1,454	1,477	23	1.6%
Transport	398	401	3	0.8%
R & D	301	421	120	39.9%
Depreciation	85	84	(1)	(1.3%)
Others	1,121	1,040	(80)	(7.2%)
Total	3,361	3,425	64	1.9%

Ordinary profit : Compared with the previous year



(unit: JPY million)



The underlined figures exclude impact of exchange rate.

Forecast for FYE Mar. 2019



(unit: JPY million)

	FYE Mar. 2018 Result	FYE Mar. 2019 Forecast	Year-over-Year
Net sales	56,520	58,000	2.6%
Operating profit	573	1,000	74.3%
Ordinary profit	820	1,200	46.3%
Profit attributable to owners of parent	631	800	26.7%
Basic earnings per share	JPY 25.91	JPY 32.83	---

Exchange Rate (average during period)	US Dollar	110.85	105
	Euro	126.67	130
	(unit: JPY) Singapore Dollar	81.74	82

Topics



※Announcement date

-Announcement of disposition of treasury shares as the stock compensation plan with transfer restrictions

Jul. 18, 2018

-Announcement of introduction of the stock compensation plan with transfer restrictions

Mar. 18, 2018

-Launching new product “TWIN SHIELD” , Catheter connection system

Apr. 18, 2018

-Launching new product “ECmoVA” , Centrifugal Blood Pump System

Mar. 29, 2018



「ECmoVA」



「TWIN SHIELD」



The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.